Pharmaceutical industry sponsorship and research outcome and quality: Systematic review

British Medical Journal

Volumn 326, Issue 7400, 2003, Pages 1167-1170

  Lexchin, Joel ^a   Bero, Lisa A ^b   Djulbegovic, Benjamin ^c   Clark, Otavio ^d  

^a YORK UNIVERSITY   (Canada)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^d Instituto do Radium de Campinas   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

CONFIDENCE INTERVAL; DRUG INDUSTRY; FINANCIAL MANAGEMENT; MEDICAL RESEARCH; METHODOLOGY; PRIORITY JOURNAL; PUBLICATION; QUALITY CONTROL; REVIEW;

EID: 0038439242     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.326.7400.1167     Document Type: Review

References (26)

1. Wyatt J. Use and sources of medical knowledge. Lancet 1991;338:1368-73.
2. Anderson JJ, Felson DT, Meenan RF. Secular changes in published clinical trials of second-line agents in rheumatoid arthritis. Arthritis Rheum 1991;34:1304-9.
3. Dorman PJ, Counsell C, Sandercock P. Reports of randomized trials in acute stroke, 1955 to 1995: what proportions were commercially sponsored? Stroke 1999;30:1995-8.
4. Pharmaceutical Research and Manufacturers of America. 2001 Industry profile. Washington, DC: PhRMA, 2003. www.phrma.org/publications/publicagons/profile02/index.cfm (accessed 6 May 2003).
5. Anis AH, Gagnon Y. Using economic evaluations to make formulary coverage decisions: so much for guidelines. Pharmacoeconomics 2000;18:55-62.
6. Hill SR, Mitchell AS, Henry DA. Problems with the interpretation of pharmacoeconomic analyses: a review of submissions to the Australian Pharmaceutical Benefits Scheme. JAMA 2000;283:2116-91.
7. Bero LA, Rennie D. Influences on the quality of published drug studies. Int J Tech Assess Health Care 1996;12:209-37.
8. Hennekens CH, Buring JE. Epidemiology in medicine. Boston: Little, Brown, and Company, 1987.
9. Cho MK, Bero LA. The quality of drug studies published in symposium proceedings. Ann Intern Med 1996;124:485-9.
10. Djulbegovic B, Lacevic M, Cantor A, Fields KK, Bennett CL, Adams JR, et al. The uncertainty principle and industry-sponsored research. Lancet 2000;356:635-8.
11. Massie BM, Rothenberg D. Publication of sponsored symposiums in medical journals. N Engl J Med 1993;328:1196-7.
12. Neumann PJ, Sandberg EA, Bell CM, Stone PW, Chapman RH. Are pharmaceuticals cost-effective? A review of the evidence. Health Affairs 2000;19(2):92-109.
13. Bekelman JE, Li Y, Gross CP. Scope and impact of financial conflicts of interest in biomedical research: a systematic review. JAMA 2003;289:454-65.
14. Rochon PA, Gurwitz JH, Simms RW, Fortin PR, Felson DT, Minaker KL, et al. A study of manufacturer-supported trials of nonsteroidal anti-inflammatory drugs in the treatment of arthritis. Arch Intern Med 1994;154:157-63.
15. Djulbegovic B. Acknowledgment of uncertainty: a fundamental means to ensure scientific and ethical validity in clinical research. Cur Oncol Rep 2001;3:389-95.
16. Saffer DJ. Design and reporting modifications in industry-sponsored comparative psychopharmacology trials. J Nerv Ment Dis 2002;190:583-92.
17. Johansen HK, Gotzsche PC. Problems in the design and reporting of trials of antifungal agents encountered during meta-analysis. JAMA 1999;282:1752-9.
18. Dickersin K, Min Y-I, Meinert CL. Factors influencing publication of research results: follow-up of applications submitted to two institutional review boards. JAMA 1992;267:374-8.
19. Easterbrook PJ, Berlin JA, Gopalan R, Matthews DR. Publication bias in clinical research. Lancet 1991;337:867-72.
20. Rennie D. Thyroid storm. JAMA 1997;277:1238-43.
21. Nathan DG, Weatherall DJ. Academia and industry: lessons from the unfortunate events in Toronto. Lancet 1999;353:771-2.
22. McCarthy M. Company sought to block paper's publication. Lancet 2000;356:1659.
23. Bero LA, Galbraith A, Rennie D. The publication of sponsored symposiums in medical journals. N Engl J Med 1992;327:1135-40.
24. Davidoff F, DeAngelis CD, Drazen JM, Højgaard L, Kotzin S, Nicholls MG, et al. Sponsorship, authorship, and accountability. N Engl J Med 2001;345:825-6.
25. Moher D, Schultz KF, Atman D, Lepage L. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. JAMA 2001;285:1987-91.
26. Horton R, Smith R. The time to register randomized trials. BMJ 1999;319:865-6.